Table 1.

FDA approved TA-specific mAb for human cancers.

	Target	Isotype	FDA approved disease
Rituximab	CD20	Chimeric IgG1	CD20 (+) low grade lymphoma1, diffuse large B cell lymphoma1, follicular lymphoma1
90Y Ibritumomab + tiuxetan	CD20	Radiolabeled murine IgG1	CD20(+) low grade lyphoma2
131I Tositumomab	CD20	Radiolabeled murine IgG1	CD20(+) low grade lyphoma3
Alemtuzumab	CD53	Humanized IgG1	Chronic lymphocytic leukemia4
Gemtuzumab + Ozogamacin	CD33	Rec. humanized IgG4- conjugated to calicheamicin	Acute myelogenous leukemia5
Tastuzumab	HER2/neu	Humanized IgG1	Her2/neu (+) breast cancer6
Cetuximab	EGFR	Chimeric IgG1	EGFR(+) Colon cancer7
Panitumumab	EGFR	Fully human IgG2	EGFR(+) Colon cancer8
Bevacizumab	VEGF	Humanized IgG1	Colon cancer9, recurrent or advance non-small cell lung cancer, metastatic breast cancer

¹Low grade lymphoma: 2nd line monotherapy; diffuse large B cell lymphoma and follicular lymphoma: 1st line chemoimmune therapy as well as maintenance for follicular lymphoma.

²2nd line monotherapy.

³2nd line monotherapy.

⁴1st and 2nd line monotherapy.

⁵>60 years of age, 2nd line monotherapy.

⁶2nd line monotherapy, adjuvant and 1st line chemoimmunetherapy.

⁷2nd line monotherapy or chemoimmune therapy.

⁸2nd line monotherapy.

⁹1st line chemoimmune therapy.